Abstract: It has been estimated that more than 280 million people suffer from depressionglobally (World Health Organization, 2012). As the leading risk factor forsuicide, depression resulted in the mortality of more than 45,000 adults in 2020(National Institute of Mental Health, 2020; Zhang et al., 2022). Although pharmaceuticalinterventions have the biomedical ability to initiate remission from depression,their long-term efficacious limitations can result in multiple recurrences ofmood destabilization over the course of a lifetime. Consequently, theseoften-lengthy non-remission periods can have a colossal impact on an individualand their family’s psychological, physiological, and socioeconomic wellbeing whenoccurring. Without the remission support of evidence-based, adjunctive,mindfulness-based cognitive therapy (MBCT), the sequelae of this debilitatingmental illness could continue to claim lives. This evidence-based practice(EBP) project was purposed to analyze the efficacy of MBCT as a therapeuticstrategy for remission maintenance in stable patients diagnosed with majordepressive disorder (MDD).The project’s setting was a local psychiatric office with 16 adult participantswho met inclusion criteria. The Patient Health Questionnaire-9 (PHQ- 9) wasused to assess depression scores at baseline and at endpoint, following an8-week intervention period that included weekly 2-hour MBCT sessions. The two-tailedpaired samples t-test was significant based on an alpha value of .05, t(15)= 12.20, p < .001, suggesting the difference in the mean of pre-test and post-testscores were significantly different from zero, with the pre-test mean being significantly higher (IntellectusStatistics, n.d.). The implication for clinical practice is for MBCT to becomebest practice to optimize the treatment of MDD. Keywords: adults, coping,depression, major depressive disorder, MDD, mental health, mindfulness, mindfulness-based cognitive therapy, PHQ-9, recurrent, relapse, remission, resilience